Mitochondria, Oxidative Damage, and Inflammation in Parkinson's Disease
- 1 June 2003
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 991 (1) , 120-131
- https://doi.org/10.1111/j.1749-6632.2003.tb07470.x
Abstract
The pathogenesis of Parkinson's disease (PD) remains obscure, but there is increasing evidence that impairment of mitochondrial function, oxidative damage, and inflammation are contributing factors. The present paper reviews the experimental and clinical evidence implicating these processes in PD. There is substantial evidence that there is a deficiency of complex I activity of the mitochondrial electron transport chain in PD. There is also evidence for increased numbers of activated microglia in both PD postmortem tissue as well as in animal models of PD. Impaired mitochondrial function and activated microglia may both contribute to oxidative damage in PD. A number of therapies targeting inflammation and mitochondrial dysfunction are efficacious in the MPTP model of PD. Of these, coenzyme Q10 appears to be particularly promising based on the results of a recent phase 2 clinical trial in which it significantly slowed the progression of PD.Keywords
This publication has 111 references indexed in Scilit:
- Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's diseaseThe FASEB Journal, 2002
- Fenoterol inhibits superoxide anion generation by human polymorphonuclear leukocytes via β2-adrenoceptor-dependent and -independent mechanismsAnnals of Allergy, Asthma & Immunology, 2002
- Role of Cyclooxygenase-2 in Neuronal Cell Cycle Activity and Glutamate-Mediated ExcitotoxicityThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Activation of PPARα or γ Reduces Secretion of Matrix Metalloproteinase 9 but Not Interleukin 8 from Human Monocytic THP-1 CellsBiochemical and Biophysical Research Communications, 2000
- Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1β and nerve growth factor in the striatumNeuroscience Letters, 1998
- Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patientsNeuroscience Letters, 1994
- 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particlesBiochemical and Biophysical Research Communications, 1990
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- Energy Metabolism and Quantal Acetylcholine Release: Effects of Botulinum Toxin, l‐Fluoro‐2,4‐Dinitrobenzene, and Diamide in the Torpedo Electric OrganJournal of Neurochemistry, 1988
- Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patientsNeuroscience Letters, 1986